Novo Nordisk and AstraZeneca are top pharmaceutical companies facing stock market challenges despite strong financial performance. Novo Nordisk's focus on diabetes and weight loss market gives it potential for growth, while AstraZeneca's diverse pipeline includes oncology and vaccines.